Alteration of the serum levels of the epidermal growth factor receptor and its ligands in patients with non-small cell lung cancer and head and neck carcinoma

被引:63
作者
Lemos-Gonzalez, Y.
Rodriguez-Berrocal, F. J.
Cordero, O. J.
Gomez, C.
Paez de la Cadena, M.
机构
[1] Univ Vigo, Dept Bioquim Genet & Inmunol, Vigo 36310, Spain
[2] Univ Santiago de Compostela, Dept Bioquim & Biol Mol, Santiago De Compostela 15782, Spain
[3] Complejo Hosp Univ Vigo, Serv Oncol Med, Vigo 36204, Spain
关键词
epidermal growth factor receptor; epidermal growth factor; transforming growth factor-alpha; amphiregulin; non-small cell lung cancer; head and neck carcinoma;
D O I
10.1038/sj.bjc.6603770
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Serum levels of the soluble epidermal growth factor receptor (sEGFR) and its ligands epidermal growth factor (EGF), transforming growth factor-alpha (TGF-alpha) and amphiregulin (AR) were measured in healthy donors and patients with non-small cell lung cancer (NSCLC) and head and neck carcinoma ( HNC). In NSCLC, we found sEGFR and EGF levels significantly lowered in patients with respect to healthy donors. In HNC patients, significantly diminished levels were found in the case of sEGFR, EGF and also AR. In both malignancies, no significant association was found between the serum levels of the molecules and the patients' gender, age or smoking habit. Only a significant association was found between the decrease of sEGFR and the absence of distant metastasis in NSCLC and the tumour stage in HNC. The most interesting result was that combining sEGFR and EGF, sensitivities of 88% in NSCLC and 100% in HNC were reached without losing specificity (97.8% in both cases). The use of discriminant analysis and logistic regression improved the sensitivity for NSCLC and the specificity for HNC. These data demonstrate a potentially interesting value of the serum levels of sEGFR and EGF, especially when combined, as markers for NSCLC and HNC.
引用
收藏
页码:1569 / 1578
页数:10
相关论文
共 39 条
  • [1] Ayude D, 2003, DIS MARKERS, V19, P267
  • [2] Baron AT, 2003, CANCER EPIDEM BIOMAR, V12, P103
  • [3] Baron AT, 2001, CANCER EPIDEM BIOMAR, V10, P1175
  • [4] Baron AT, 1999, CANCER EPIDEM BIOMAR, V8, P129
  • [5] Baselga J, 2002, ONCOLOGIST, V7, P2
  • [6] Carney Walter P., 2002, Proceedings of the American Association for Cancer Research Annual Meeting, V43, P47
  • [7] Role of HER receptors family in development and differentiation
    Casalini, P
    Iorio, MV
    Galmozzi, E
    Ménard, S
    [J]. JOURNAL OF CELLULAR PHYSIOLOGY, 2004, 200 (03) : 343 - 350
  • [8] ELEVATED SERUM LEVELS OF TRANSFORMING GROWTH-FACTOR-ALPHA IN BREAST-CANCER PATIENTS
    CHAKRABARTY, S
    HUANG, S
    MOSKAL, TL
    FRITSCHE, HA
    [J]. CANCER LETTERS, 1994, 79 (02) : 157 - 160
  • [9] Detection of serum transforming growth factor-alpha in patients of primary epithelial ovarian cancers by enzyme immunoassay
    Chien, CH
    Huang, CC
    Lin, YH
    Shen, J
    Chow, SN
    [J]. GYNECOLOGIC ONCOLOGY, 1997, 66 (03) : 405 - 410
  • [10] Detection of transforming growth factor-α in the serum of gastric carcinoma patients
    Choi, JH
    Kim, HC
    Lim, HY
    Nam, DK
    Kim, HS
    Yi, SY
    Shim, KS
    Han, WS
    [J]. ONCOLOGY, 1999, 57 (03) : 236 - 241